Bioinspired Nanoparticles Engineered for Enhanced Delivery to the Bone
Source abstract
Abstract
Targeting therapeutic agents to specific organs in the body remains a challenge despite advances in the science of systemic drug delivery. We have engineered a programmable-bioinspired nanoparticle (P-BiNP) delivery system to simultaneously target the bone and increase uptake in homotypic tumor cells by coating polymeric nanoparticles with programmed cancer cell membranes. This approach is unique in that we have incorporated relevant clinical bioinformatics data to guide the design and enhancement of biological processes that these nanoparticles are engineered to mimic. To achieve this, an analysis of RNA expression from metastatic prostate cancer patients identified ITGB3 (a subunit of integrin αVβ3) as overexpressed in patients with bone metastasis. Cancer cells were stimulated to increase this integrin expression on the cell surface, and these membranes were subsequently used to coat cargo carrying polymeric nanoparticles. Physicochemical optimization and characterization of the P-BiNPs showed desirable qualities regarding size, ζ potential, and stability. In vitro testing confirmed enhanced homotypic binding and uptake in cancer cells. P-BiNPs also demonstrated improved bone localization in vivo with a murine model. This novel approach of identifying clinically relevant targets for dual homotypic and bone targeting has potential as a strategy for treatment and imaging modalities in diseases that affect the bone as well as broader implications for delivering nanoparticles to other organs of interest.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Extracellular vesicles in disease
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
University of North Texas Health Science Center, 3500 Camp Bowie Boulevard, Fort Worth, Texas 76107, United States
Funding
National Cancer Institute · Urology Care Foundation · Cancer Prevention and Research Institute of Texas · UNTHSC Seed Grant · UNTHSC, GSBS New and Early Stage Faculty Investigator Research Program Seed Grant
References (26)
Show source-provided references
1. 10.1016/j.jconrel.2010.08.02710.1016/j.jconrel.2010.08.027 ↗
2. 10.1016/j.addr.2013.11.00910.1016/j.addr.2013.11.009 ↗
3. 10.1038/nnano.2007.38710.1038/nnano.2007.387 ↗
4. 10.1016/j.nano.2012.05.01510.1016/j.nano.2012.05.015 ↗
5. 10.1038/nrc326110.1038/nrc3261 ↗
6. 10.1186/s13046-017-0578-110.1186/s13046-017-0578-1 ↗
7. 10.1073/pnas.110663410810.1073/pnas.1106634108 ↗
8. 10.1002/ijc.2602410.1002/ijc.26024 ↗
9. 10.1002/pros.2050010.1002/pros.20500 ↗
10. 10.1021/nl500618u10.1021/nl500618u ↗
11. Glinsky V. V. · Cancer research · 2003 · 63 · 3805
12. 10.1074/jbc.M20959020010.1074/jbc.M209590200 ↗
13. 10.1021/acsnano.7b0253310.1021/acsnano.7b02533 ↗
14. 10.1371/journal.pone.012280510.1371/journal.pone.0122805 ↗
15. Thalmann G. N. · Cancer research · 1994 · 54 · 2577
16. 10.1039/C3NR06371B10.1039/C3NR06371B ↗
17. 10.1615/CritRevTherDrugCarrierSyst.201300647510.1615/CritRevTherDrugCarrierSyst.2013006475 ↗
18. 10.1021/acs.nanolett.6b0278610.1021/acs.nanolett.6b02786 ↗
19. 10.1158/1078-0432.CCR-14-135810.1158/1078-0432.CCR-14-1358 ↗
20. 10.1023/A:100651201860910.1023/A:1006512018609 ↗
21. van der Plujim G. · Laboratory investigation · 1997 · 77 · 665
22. 10.1002/(SICI)1097-4652(199809)176:3<482::AID-JCP5>3.0.CO;2-K10.1002/(SICI)1097-4652(199809)176:3<482::AID-JCP5>3.0.CO;2-K ↗
23. 10.3892/ijo.17.6.123710.3892/ijo.17.6.1237 ↗
24. 10.1016/j.pharmthera.2010.09.01110.1016/j.pharmthera.2010.09.011 ↗
25. 10.1016/j.jconrel.2015.07.01910.1016/j.jconrel.2015.07.019 ↗
26. 10.1039/C6CS00636A10.1039/C6CS00636A ↗